

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Psychiatry

**Manuscript NO:** 65128

**Title:** Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?

**Reviewer's code:** 02729669

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-03-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-18 06:18

**Reviewer performed review:** 2021-04-18 14:10

**Review time:** 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

a. Abstract: Adequate b. Keywords: Appropriate c. The authors discussed about the early intervention in OCD, before the conclusion. But, it is not clear, whether they want to discuss about the initiation of treatment in OCD early in order to reduce the duration of untreated illness or they want to discuss about early initiation of anti-glutamatergic agents in the management of OCD. d. The authors may also discuss the role of neuromodulation techniques, that also modulate the glutamateric system.